Cellectar Completes Enrollment In Phase I Clinical Trial Of Lead Drug Candidate (131)I-CLR1404 For The Treatment Of Solid Malignancies
Cellectar, Inc., a privately held radiopharmaceutical company that designs and develops products to detect, treat and monitor human cancers, announced that enrollment for its Phase I dosimetry trial for its lead drug candidate, (131)I-CLR1404 has been completed. Results of this trial will be used to set the starting dose in a follow-on Phase I dose escalation study planned for later this year. Institutions that participated in the trial include City of Hope, Duke University Medical Center, Georgetown University/Lombardi Cancer Center, and Johns Hopkins Hospital... (Source: Health News from Medical News Today)div id=medwormpbiMedWorm Message:/i/b Get the very latest Swine Flu news via the MedWorm ba href=http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29t=Swine+Fluf=infectiousdiseasesr=Anyo=d target =_selfSwine Flu RSS news feed/a/b - updated hourly from thousands of authoritative health and news sources./p/div
Acupuncture 'provides no help with IVF' say fertility doctors
With conflicting conclusions about the value of the complementary medicines in aiding IVF, members of the British Fertility Society set out to obtain a definitive answer. (Source: the Mail online | Health)
